Dr. Philips joined the Division of Pulmonology in July 2017 and previously was senior statistician at the MRC Clinical Trials Unit at UCL in London. He has worked on late-phase clinical trials in tuberculosis for more than a decade, most recently as trial statistician in the REMoxTB and RIFAQUIN phase III trials. He leads the statistics core of the African/European PanACEA consortium evaluating novel regimens for the treatment of TB, designing the PanACEA MAMS-TB phase II trial with a Multi-Arm Multi-Stage (MAMS) design. He is lead statistician for the USAID-funded STREAM Stage 1 trial evaluating the new 9-month MDR-TB regimen. Ongoing methodological areas of interest include the evaluation and use of surrogate endpoints, the conduct and analysis of non-inferiority trials and trial design with a focus on adaptive designs. He is an associate editor for the journal Trials.
The objective of Dr. Philips’ research continues to be to design, implement, and optimize clinical trials for new treatments for tuberculosis in order to deliver safer and more efficacious regimens for patients. A key focus of his research has been to improve the design of TB clinical trials through implementation of novel methodology so that regimen development is faster and more efficient. This was motivated by his PhD thesis evaluating surrogate endpoints for TB trials, and has grown in a number of areas through the various collaborations and consortia that he contributes to.